Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
1.
Insights Imaging ; 4(1): 103-9, 2013 Feb.
Article in English | MEDLINE | ID: mdl-23225253

ABSTRACT

OBJECTIVES: To obtain medical students' evaluation of the quality of undergraduate radiology teaching received, preferred teaching methods and resources. This is a follow-up project to an earlier study of junior doctors who felt that radiology teaching left them ill prepared for medical practice. METHODS: A questionnaire to third and fifth year medical students undertaking clinical rotations at Newcastle University, UK. RESULTS: The questionnaire was completed by 57/60 (95 %) of third and 37/40 (93 %) of final year medical students. Students received minimal radiology teaching in pre-clinical years, feeling this was insufficient. The majority of students rated interactive case-based teaching as effective. Self-directed learning resources such as textbooks, journals and even online learning modules were perceived as less effective. Other types of web resources rated higher. Motivation for most students when studying radiology was to achieve learning objectives needed to pass their next exams and/or to improve as a doctor. CONCLUSIONS: Medical students criticise the lack of radiology teaching in pre-clinical undergraduate years. Radiology teaching should be represented in all undergraduate years, preferably delivered via interactive teaching sessions. Currently available e-learning modules do not meet the students' learning needs and there is a call for reliable, up-to-date open access electronic resources. MAIN MESSAGES: • Radiology teaching should be represented in all pre-clinical and clinical undergraduate years. • Medical students rate interactive case-based teaching sessions as very effective. • There is a call for reliable, up-to-date open access electronic resources for medical students.

4.
Lancet Neurol ; 6(5): 397-406, 2007 May.
Article in English | MEDLINE | ID: mdl-17434094

ABSTRACT

BACKGROUND: Hyperglycaemia after acute stroke is a common finding that has been associated with an increased risk of death. We sought to determine whether treatment with glucose-potassium-insulin (GKI) infusions to maintain euglycaemia immediately after the acute event reduces death at 90 days. METHODS: Patients presenting within 24 h of stroke onset and with admission plasma glucose concentration between 6.0-17.0 mmol/L were randomly assigned to receive variable-dose-insulin GKI (intervention) or saline (control) as a continuous intravenous infusion for 24 h. The purpose of GKI infusion was to maintain capillary glucose at 4-7 mmol/L, with no glucose intervention in the control group. The primary outcome was death at 90 days, and the secondary endpoint was avoidance of death or severe disability at 90 days. Additional planned analyses were done to determine any differences in residual disability or neurological and functional recovery. The trial was powered to detect a mortality difference of 6% (sample size 2355), with 83% power, at the 5% two-sided significance level. This study is registered as an International Standard Randomised Controlled Trial (number ISRCTN 31118803) FINDINGS: The trial was stopped due to slow enrolment after 933 patients were recruited. For the intention-to-treat data, there was no significant reduction in mortality at 90 days (GKI vs control: odds ratio 1.14, 95% CI 0.86-1.51, p=0.37). There were no significant differences for secondary outcomes. In the GKI group, overall mean plasma glucose and mean systolic blood pressure were significantly lower than in the control group (mean difference in glucose 0.57 mmol/L, p<0.001; mean difference in blood pressure 9.0 mmHg, p<0.0001). INTERPRETATION: GKI infusions significantly reduced plasma glucose concentrations and blood pressure. Treatment within the trial protocol was not associated with significant clinical benefit, although the study was underpowered and alternative results cannot be excluded.


Subject(s)
Glucose/administration & dosage , Hyperglycemia/drug therapy , Hyperglycemia/etiology , Insulin/administration & dosage , Potassium/administration & dosage , Stroke/complications , Aged , Aged, 80 and over , Blood Glucose/drug effects , Blood Glucose/metabolism , Blood Pressure/drug effects , Disabled Persons/statistics & numerical data , Drug Combinations , Female , Glucose/therapeutic use , Humans , Hyperglycemia/blood , Infusions, Intravenous , Insulin/therapeutic use , Male , Potassium/therapeutic use , Stroke/mortality , Stroke/physiopathology , Treatment Failure
5.
J Cataract Refract Surg ; 32(1): 60-6, 2006 Jan.
Article in English | MEDLINE | ID: mdl-16516780

ABSTRACT

PURPOSE: To examine changes in visual, psychological, and functional disability in older people waiting for cataract extraction and 6 months after surgery. SETTING: Community-based study in Northeast England. METHODS: Participants were 92 patients (mean age 78.1 years +/- 6.5 [SD], 79% female) with age-related cataract. Questionnaires were administered at time of listing for cataract extraction, 2 weeks preoperatively, and 2 and 6 months after surgery to assess visual symptoms and function, anxiety and depression, perceived health status, cognition, and activities of daily living. RESULTS: Mean waiting time was 265 +/- 64.4 days. Forty-six patients had first-eye surgery, 39 had second-eye surgery, and 7 had sequential-eye surgery (both eyes operated on during follow-up). During the waiting period, there were no significant changes in visual symptoms, cognition, or functional abilities. However, perceived health status, anxiety, and depression improved significantly during this time. For first- and second-eye patients, surgery resulted in significant improvements in all questionnaire scores, except activities of daily living. CONCLUSIONS: Despite waiting 9 months for cataract surgery, patients did not decline in visual symptoms, social functioning, or cognition. In first- and second-eye patients, successful cataract extraction resulted in significant gains in visual function, cognition, and emotional and general well-being. The benefits of cataract surgery in older people extended beyond simple measures of visual acuity.


Subject(s)
Disabled Persons/psychology , Phacoemulsification , Recovery of Function/physiology , Visual Acuity/physiology , Activities of Daily Living/psychology , Aged , Anxiety/physiopathology , Cognition/physiology , Depression/physiopathology , Disabled Persons/rehabilitation , Female , Health Status , Humans , Lens Implantation, Intraocular , Male , Surveys and Questionnaires , United Kingdom , Waiting Lists
8.
Stroke ; 35(1): 122-6, 2004 Jan.
Article in English | MEDLINE | ID: mdl-14671236

ABSTRACT

BACKGROUND AND PURPOSE: Poststroke hyperglycemia (PSH) is a frequent finding for which there is currently no evidence to justify routine treatment. The United Kingdom Glucose Insulin in Stroke Trial (GIST-UK) is the only trial of glucose modulation in acute stroke from which evidence can be derived for the immediate management of PSH. Using safety-monitoring data from the trial we aimed to describe the immediate recovery of PSH in treated and control patients, thus providing evidence for the use of glucose/potassium/insulin (GKI) infusions as a means of maintaining euglycemia. METHODS: GIST-UK is a multicenter randomized controlled trial of GKI or saline infusions in acute stroke patients presenting with mild to moderate hyperglycemia (admission plasma glucose, 6.0 to 17 mmol). We analyzed the capillary BM and plasma glucose values in the 2 treatment groups to describe the recovery of PSH and the effectiveness of the GIST treatment regimen in maintaining euglycemia. RESULTS: The majority of patients have only moderate PSH (mean plasma glucose, 8.37+/-SD 2.13). Without specific intervention, mean plasma glucose levels decline spontaneously. Treatment with the GIST GKI regimen rapidly achieved euglycemia at significantly lower levels than with saline hydration alone. Euglycemia was achieved with a median of 2 changes to the GKI regimen and a low risk of hypoglycemia. CONCLUSIONS: GKI infusions as described in the GIST trial are a safe and effective means of correcting PSH and maintaining euglycemia in the acute phase of stroke. The clinical benefits of routine management of hyperglycemia remain to be determined.


Subject(s)
Blood Glucose/drug effects , Hyperglycemia/drug therapy , Hyperglycemia/physiopathology , Insulin/therapeutic use , Stroke/physiopathology , Acute Disease , Aged , Disease Progression , Drug Therapy, Combination , Female , Glucose/administration & dosage , Glucose/therapeutic use , Humans , Hyperglycemia/etiology , Infusions, Intravenous , Insulin/administration & dosage , Male , Observer Variation , Potassium/administration & dosage , Potassium/blood , Potassium/therapeutic use , Sodium/blood , Stroke/complications , Treatment Outcome
9.
Age Ageing ; 33(1): 71-7, 2004 Jan.
Article in English | MEDLINE | ID: mdl-14695867

ABSTRACT

BACKGROUND: diabetes mellitus not only increases the risk of ischaemic stroke two- to four-fold but also adversely inXuences prognosis. The prevalence of recognised diabetes mellitus in acute stroke patients is between 8 and 20%, but between 6 and 42% of patients may have undiagnosed diabetes mellitus before presentation. Post-stroke hyperglycaemia is frequent and of limited diagnostic value and the oral glucose tolerance test assumes that the patient is clinically stable and eating normally. There is a need for a simple and reliable method to predict new diabetes mellitus in acute stroke patients. OBJECTIVES: to determine the prevalence of unrecognised diabetes mellitus and impaired glucose tolerance on hospital admission and 12 weeks later in acute stroke patients with post-stroke hyperglycaemia > or = 6.1 mmol/l. To measure the accuracy of hyperglycaemia and elevated glycosylated haemoglobin concentration in predicting the presence of unrecognised diabetes mellitus at 12 weeks. DESIGN: acute (<24 hours) stroke patients (cerebral infarction and primary intracerebral haemorrhage) with admission hyperglycaemia between 6.0 and 17 mmol/l and without a previous history of insulin-treated diabetes mellitus who were randomised into the Glucose Insulin in Stroke Trial between October 1997 and May 1999 were studied. The Glucose Insulin in Stroke Trial is a randomised controlled trial investigating the benefits of maintaining euglycaemia in acute stroke patients with mild to moderate hyperglycaemia. At 12 weeks, survivors underwent a 75 g oral glucose tolerance test. The positive predictive value and negative predictive value of admission plasma glucose > or = 6.1 mmol/l and elevated glycosylated haemoglobin concentration in predicting the presence of diabetes mellitus were used to estimate the prevalence of unrecognised diabetes mellitus in a consecutive series of 582 acute stroke admissions. RESULTS: 582 consecutive acute stroke patients were assessed for eligibility for the Glucose Insulin Stroke Trial, of whom 83 (14%) had recognised diabetes mellitus. One hundred and forty-two patients were randomised and 62 underwent a 3-month oral glucose tolerance test, of whom 26 (42%) had normal glucose tolerance, 23 (37%) had impaired glucose tolerance and 13 (21%) had diabetes mellitus. Admission plasma glucose > or = 6.1 mmol/l and glycosylated haemoglobin > or = 6.2% predicted the presence of previously unrecognised diabetes mellitus at 12 weeks with a positive predictive value of 80% and negative predictive value of 96%. The estimated prevalence of unrecognised diabetes mellitus in the total series of acute stroke admissions was 16-24%. CONCLUSIONS: one-third of all acute stroke patients may have diabetes mellitus. For patients presenting with post-stroke hyperglycaemia, impaired glucose tolerance or diabetes mellitus is present in two-thirds of survivors at 12 weeks. Admission plasma glucose > or = 6.1 mmol/l combined with glycosylated haemoglobin > or = 6.2% are good predictors of the presence of diabetes mellitus following stroke.


Subject(s)
Diabetes Complications , Glucose Intolerance/complications , Stroke/complications , Acute Disease , Adult , Aged , Aged, 80 and over , Diabetes Mellitus/epidemiology , Female , Glucose Intolerance/epidemiology , Glucose Tolerance Test , Glycated Hemoglobin/analysis , Humans , Male , Middle Aged , Predictive Value of Tests , Prevalence
10.
Int J Geriatr Psychiatry ; 18(12): 1121-34, 2003 Dec.
Article in English | MEDLINE | ID: mdl-14677145

ABSTRACT

BACKGROUND: The public health impact of cognitive decline and dementia is increasing as the population ages. Studies exploring therapies or risk factors for cognitive impairment require understanding of expected age-related decline. OBJECTIVE: To establish the rate of age-related cognitive decline in the general elderly population. DESIGN: Systematic review of studies of cognitive decline in the general elderly population. Medline, Embase and PsycINFO databases were searched using an adapted version of McMaster's aetiology, causation and harm strategies and the Cochrane Dementia and Cognitive Impairment Group strategy. Grey literature was explored and experts contacted. A second observer was involved at all stages and quality appraisal of included studies was performed. Included studies were representative, community-based, cohort studies of people aged over 60, incorporating individuals with dementia. RESULTS: Identification of 5990 abstracts and retrieval of 163 full texts led to inclusion of 19 papers. Heterogeneity made narrative review the appropriate method of data synthesis. Some degree of cognitive impairment with increasing age was found in all studies, although the extent varied. The prevalence of cognitive impairment and the rate of decline increased with age. Studies were of variable quality. CONCLUSIONS: Cognitive decline is almost universal in the general elderly population and increases with age. Improved communication between researchers and between clinicians to identify a core minimum data set of neuropsychological tests that could be used in different populations would support consistent study design and meta-analysis, helping to quantify the true rate of cognitive decline in the elderly and assisting diagnosis in clinical practice.


Subject(s)
Cognition Disorders/physiopathology , Aged , Aged, 80 and over , Aging/physiology , Algorithms , Cognition Disorders/etiology , Cohort Studies , Disease Progression , Humans , Middle Aged , Neuropsychological Tests
12.
Age Ageing ; 31 Suppl 3: 5, 2002 Nov.
Article in English | MEDLINE | ID: mdl-12450920
SELECTION OF CITATIONS
SEARCH DETAIL
...